Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 162, pseudogene (RNU6-162P) is a processed pseudogene derived from the highly conserved U6 small nuclear RNA (U6 snRNA) gene family. U6 snRNA is an essential component of the spliceosome complex involved in the splicing of pre-mRNA, but *RNU6-162P* itself is a non-functional copy produced via retrotransposition, primarily by L1/LINE-1 elements. It is annotated as a non-coding RNA pseudogene and does not produce a functional RNA or protein product. There is no evidence that this pseudogene acts as a therapeutic target, nor is it known to participate in drug interactions, disease mechanisms, or clinical biomarker pathways. The classification and study of such pseudogenes provide insights into genome evolution and retrotransposon activity, but they lack direct biomedical relevance as functional molecular targets. Because the entity is a pseudogene and not an active gene product, it should not be considered a drug target, therapeutic target, or functional biological molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 162, pseudogene (RNU6-162P).